Maia Kayal, MD, MS, and Jonathan Kay, MD, define interchangeability and review the details of a switching study. Ryan Haumschild, PharmD, MS, MBA: With all those different options, we know some of the ...
As the open question around interchangeable biosimilars in the US continues to drive the discussion on what the US Food and Drug Administration (FDA) will require for such a designation, some experts ...
Interchangeability impacts payer incentives, provider perceptions, and biosimilar adoption rates, with formulary status and complexity as barriers. Regulatory and legislative solutions are needed to ...
Interchangeable biosimilar products would not be allowed to disclose or explain their interchangeability designations in their products’ labels under FDA’s new draft guidance. FDA justified its ...
The U.S. Food and Drug Administration (FDA) recently issued new revised draft guidance on “Labeling for Biosimilar and Interchangeable Biosimilar Products,” which most notably dispenses with any ...
A top biologics official with the US Food and Drug Administration (FDA) explained the agency’s rationale in proposing to eliminate interchangeability designations in prescriber labeling for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results